Bulk Pharmaceutical API Sources for febuxostat

Bulk Pharmaceutical API Sources for febuxostat

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-425
Molport		MolPort-005-940-740
Selleck Chemicals		S1547
BioChemPartner		BCPP000233

Febuxostat Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes key bulk Active Pharmaceutical Ingredient (API) sources for febuxostat, a xanthine oxidase inhibitor used in the management of hyperuricemia in patients with gout. The analysis focuses on manufacturing capabilities, regulatory compliance, and market positioning of prominent API suppliers.

What are the primary global suppliers of febuxostat API?

The global supply of febuxostat API is concentrated among a limited number of manufacturers, primarily located in India and China. These suppliers cater to both generic drug manufacturers and contract manufacturing organizations (CMOs) worldwide. Key players include:

• Anesta Pharmaceutical Pvt. Ltd. (India): An established API manufacturer with significant capacity for febuxostat production. The company holds certifications from various international regulatory bodies.
• Apotex Research Pvt. Ltd. (India): A subsidiary of Apotex Inc., this facility is a major producer of febuxostat API, serving both domestic and international markets.
• Divi’s Laboratories Limited (India): Known for its large-scale API manufacturing, Divi's Laboratories is a significant supplier of febuxostat, emphasizing quality control and regulatory adherence.
• Laurus Labs Limited (India): A rapidly growing pharmaceutical company with substantial API manufacturing capabilities, including febuxostat. Laurus Labs is recognized for its integrated manufacturing processes.
• Neuland Laboratories Limited (India): This company manufactures febuxostat API and offers custom synthesis services. They have a strong regulatory track record.
• Zydus Lifesciences Limited (India): Formerly Cadila Healthcare, Zydus is a diversified pharmaceutical company with a significant API division that produces febuxostat.
• Jiangsu Hansoh Pharmaceutical Co., Ltd. (China): A major Chinese pharmaceutical enterprise with substantial API manufacturing capacity, including febuxostat.
• Qilu Pharmaceutical Co., Ltd. (China): Another prominent Chinese API manufacturer that produces febuxostat for global distribution.
• Wuhan Yuancheng Gongchuang Technology Co., Ltd. (China): This company lists febuxostat API among its offerings and serves various international markets.

These suppliers vary in their production volumes, lead times, and pricing structures. Companies seeking to secure a reliable supply chain should conduct thorough due diligence on each potential partner.

What regulatory approvals and certifications do febuxostat API manufacturers hold?

Regulatory compliance is critical for API manufacturers supplying to regulated markets such as the United States, European Union, and Japan. Manufacturers of febuxostat API typically pursue and maintain the following:

• US Food and Drug Administration (FDA) Approval: Facilities manufacturing APIs for the U.S. market must comply with FDA regulations. This often involves successful FDA inspections and the presence of febuxostat API in Drug Master Files (DMFs) submitted to the FDA.
• European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificate of Suitability (CEP): A CEP demonstrates that the quality of the API is suitably controlled by the manufacturing process. This is a key document for marketing authorization applications in Europe.
• World Health Organization (WHO) Good Manufacturing Practices (GMP): While not always a direct market entry requirement for all regions, WHO GMP certification signifies adherence to international quality standards.
• National Regulatory Authority Approvals: Manufacturers also seek approvals from regulatory bodies in other key markets, such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada.
• ISO Certifications: While not specific to pharmaceuticals, ISO 9001 and ISO 14001 certifications indicate robust quality management and environmental management systems.

Table 1: Representative Regulatory Compliance Status of Key Febuxostat API Suppliers

Supplier Name	FDA Inspected	CEP Issued	Other Key Approvals (e.g., PMDA)	Notes
Anesta Pharmaceutical Pvt. Ltd.	Yes	Available	N/A	Focus on quality and compliance for regulated markets.
Apotex Research Pvt. Ltd.	Yes	Available	N/A	Integral part of a global pharmaceutical supply chain, adhering to stringent quality controls.
Divi’s Laboratories Limited	Yes	Available	Yes	Holds multiple DMFs and CEPs for various APIs, including febuxostat, supporting global market access.
Laurus Labs Limited	Yes	Available	Yes	Strong emphasis on R&D and regulatory filings; holds a significant number of DMFs and CEPs.
Neuland Laboratories Limited	Yes	Available	Yes	Known for robust regulatory expertise and multiple DMF/CEP filings for its API portfolio.
Zydus Lifesciences Limited	Yes	Available	Yes	Significant global presence with API facilities undergoing regular audits by international regulatory agencies.
Jiangsu Hansoh Pharmaceutical Co., Ltd.	Yes	Available	Yes	One of China's largest API manufacturers; extensive experience in meeting diverse international regulatory requirements.
Qilu Pharmaceutical Co., Ltd.	Yes	Available	Yes	Strong production capacity and a focus on global compliance standards.
Wuhan Yuancheng Gongchuang Tech. Co., Ltd.	May Vary	May Vary	May Vary	Documentation and regulatory status may vary; requires direct verification for specific markets.

Note: "Available" indicates that the supplier typically provides this documentation for its febuxostat API. Direct verification with the supplier for current status is recommended.

What are the typical quality specifications for febuxostat API?

Quality specifications for febuxostat API are dictated by pharmacopoeias and customer requirements. The most common standards include:

• Assay: Typically ≥ 98.0% to ≤ 102.0% (on an anhydrous and solvent-free basis).
• Related Substances (Impurities): Limits are set for specific known impurities and unspecified impurities. These are usually expressed as percentages of the main compound. For example, individual unknown impurities are often limited to ≤ 0.10%, and total impurities to ≤ 0.50% or ≤ 1.0%. Specific impurity profiles are crucial and must comply with ICH Q3A guidelines.
• Loss on Drying: Typically ≤ 0.5% or ≤ 1.0%.
• Residue on Ignition (Sulphated Ash): Typically ≤ 0.1%.
• Heavy Metals: Limits are set according to pharmacopoeial standards (e.g., ≤ 10 ppm or ≤ 20 ppm).
• Residual Solvents: Limits must comply with ICH Q3C guidelines. Common solvents used in synthesis include ethanol, isopropanol, ethyl acetate, and toluene, each with specific permissible limits.
• Particle Size Distribution: Can be a critical parameter for formulation development and dissolution profiles, especially for solid oral dosage forms. Specifications may include D10, D50, and D90 values.
• Polymorphism: Febuxostat can exist in different polymorphic forms, which can affect its solubility, stability, and bioavailability. Manufacturers must control and consistently produce the desired polymorphic form.

Table 2: Key Quality Parameters for Febuxostat API

Parameter	Typical Specification Range	Pharmacopoeia Reference (if applicable)	Significance
Assay	≥ 98.0% to ≤ 102.0%	USP, EP, JP	Ensures correct therapeutic dosage.
Impurities (Individual Unknown)	≤ 0.10%	ICH Q3A	Controls potentially harmful byproducts of synthesis.
Impurities (Total Unknown)	≤ 0.50%	ICH Q3A	Overall control of synthetic byproducts.
Loss on Drying	≤ 0.5% to ≤ 1.0%	USP, EP, JP	Indicates water content, affecting stability and accurate weighing.
Residue on Ignition	≤ 0.1%	USP, EP, JP	Measures inorganic impurities.
Heavy Metals	≤ 10 ppm / ≤ 20 ppm	USP, EP, JP	Limits potentially toxic metallic contaminants.
Residual Solvents	Varies by solvent	ICH Q3C	Controls levels of solvents used in manufacturing, impacting safety.
Particle Size Distribution	Specified by customer	Not universally defined	Influences dissolution rate, flowability, and tablet compression properties.

What is the market landscape for febuxostat API?

The febuxostat API market is primarily driven by the demand for generic febuxostat drug products following patent expiries in various regions. The market is characterized by:

• Competition: A moderate to high level of competition exists among API manufacturers, leading to price sensitivity. Manufacturers in India and China generally offer competitive pricing.
• Backward Integration: Some larger pharmaceutical companies or API manufacturers may engage in backward integration to control the supply and cost of key starting materials, thereby enhancing their competitive edge.
• Quality and Regulatory Compliance: Despite price competition, the ability to consistently meet stringent quality standards and provide comprehensive regulatory documentation (DMFs, CEPs) is a significant differentiator. Manufacturers with strong regulatory track records command higher market share in regulated markets.
• Capacity and Lead Times: Reliable production capacity and reasonable lead times are crucial for securing long-term supply agreements. Suppliers with large-scale manufacturing facilities can often offer better scalability and responsiveness.
• Supply Chain Stability: Geopolitical factors, raw material availability, and logistical challenges can impact supply chain stability. Companies are increasingly focusing on diversifying their supplier base to mitigate these risks.
• Emerging Markets: While North America and Europe represent the largest markets for febuxostat, demand is growing in emerging economies as healthcare access improves and diagnostic capabilities for gout increase.

What are the key considerations for sourcing febuxostat API?

Sourcing febuxostat API requires a strategic approach focusing on several critical factors:

• Regulatory Status: Verify the manufacturer's regulatory compliance for the target markets. Review DMFs and CEPs for completeness and accuracy. Conduct site audits if necessary.
• Quality Assurance: Ensure the API meets pharmacopoeial standards and customer-specific requirements. Review Certificates of Analysis (CoAs) and impurity profiles. Understand the analytical methods used.
• Manufacturing Capacity and Reliability: Assess the supplier's production capacity to meet current and future demand. Evaluate their track record for on-time delivery and supply chain reliability.
• Cost and Commercial Terms: Obtain competitive quotes and negotiate favorable commercial terms, including payment schedules, minimum order quantities (MOQs), and Incoterms.
• Technical Support: The supplier should be able to provide robust technical support, including assistance with regulatory filings, troubleshooting, and process development.
• Intellectual Property (IP): Understand the patent landscape related to febuxostat and its manufacturing processes. Ensure that sourcing from a particular manufacturer does not infringe on existing patents.
• Supplier Audits: Conduct regular audits of manufacturing facilities to verify compliance with GMP, quality systems, and ethical standards.
• Change Control Management: Establish clear procedures for managing manufacturing process changes and their impact on API quality.

Key Takeaways

The global febuxostat API market is characterized by a significant presence of manufacturers in India and China, offering competitive pricing and substantial production capacities. Regulatory compliance, particularly FDA and EDQM approvals, is paramount for market access to developed countries. Key quality parameters include assay, strict impurity limits, and residual solvent control, often guided by pharmacopoeial standards and ICH guidelines. Sourcing decisions should prioritize regulatory adherence, consistent quality, manufacturing reliability, competitive pricing, and robust technical support, alongside a proactive approach to supply chain risk management.

---

Frequently Asked Questions

1. How can I verify the regulatory compliance of a febuxostat API supplier?

Verification involves requesting and reviewing official documentation such as DMFs, CEPs, and recent inspection reports from regulatory agencies (e.g., FDA, EMA). Direct communication with the regulatory affairs department of the supplier is essential. Site audits, whether conducted by your company or a third-party auditor, can provide further validation.

2. What are the critical impurities to monitor in febuxostat API?

Critical impurities are those with toxicological concerns or those that can impact the stability and efficacy of the final drug product. Manufacturers must control specified identified impurities and set limits for unspecified impurities according to ICH Q3A guidelines. Common concerns include process-related impurities and degradation products. A thorough review of the supplier's impurity profile and analytical methods is crucial.

3. How does particle size distribution affect febuxostat API?

Particle size distribution influences several critical aspects of drug product manufacturing and performance. For oral solid dosage forms, it affects powder flow, compressibility during tableting, and, most importantly, the dissolution rate of the API. A controlled particle size can lead to consistent bioavailability and therapeutic effect. Specifications for particle size are typically determined by the formulation scientist based on the intended dosage form and desired release characteristics.

4. What are the typical lead times for bulk febuxostat API orders?

Lead times can vary significantly based on the supplier's current production schedule, order volume, and raw material availability. For established suppliers with ready inventory or predictable production cycles, lead times might range from 4 to 8 weeks for standard orders. However, for large volumes or custom specifications, lead times can extend to 12 weeks or more. It is advisable to confirm lead times directly with potential suppliers when placing an order.

5. What is the impact of patent expiry on febuxostat API sourcing?

Patent expiry for the febuxostat molecule itself (composition of matter patent) and for key manufacturing processes has opened the market to generic API manufacturers. This has intensified competition, leading to downward pressure on prices and an increased focus on efficiency and scale for API producers. Sourcing from multiple qualified manufacturers becomes a viable strategy to ensure supply security and competitive pricing in the post-patent landscape.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guideline for Residual Solvents (ICH Q3C). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). Impurities: Guideline for New Drug Substances (ICH Q3A). [5] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. [6] European Pharmacopoeia. (n.d.). Monographs.